cusatuzumab

Home
Ligands
cusatuzumab

GtoPdb Ligand ID: 9778

Synonyms: ARGX-110 | ARGX110 | clone 41D12

Comment: Cusatuzumab (ARGX-110) is a highly potent, afucosylated, humanized IgG1 anti-CD70 antibody being investigated for potential against solid and hematological tumours [2].

Summary
Biological activity
Clinical data
References
Immunopharmacology

No information available.

No information available.

Summary of Clinical Use
ARGX-110 is in clinical trials for various cancers; Max Phase 2. Click here to view ClinicalTrials.gov's list of registered ARGX-110 trials.

Summary of Clinical Use

ARGX-110 is in clinical trials for various cancers; Max Phase 2. Click here to view ClinicalTrials.gov's list of registered ARGX-110 trials.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT04241549	A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment	Phase 1 Interventional	Janssen Pharmaceutical K.K.